within Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DC02_Pranlukast;

model Pranlukast
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.063,
    Cl = 1.4166666666666665e-06,
    adminDuration = 600,
    adminMass = 225 / 1000000,
    adminCount = 1,
    Vd = 0.0092,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01,
    Tlag = 10.020000000000001,
    Vdp = 0.012199999999999999,
    k12 = 1.7222222222222224e-06,
    k21 = 1.7222222222222224e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pranlukast</td></tr><tr><td>ATC code:</td><td>R03DC02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>225</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>9.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5.1</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pranlukast is a leukotriene receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of allergic rhinitis. It works by blocking leukotriene D4 at the cysteinyl leukotriene receptor, reducing inflammation and bronchoconstriction. Pranlukast is approved for use in Japan and some other countries, but not in the United States or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Asano, K, et al., &amp; Ishizaka, A (2009). Impact of pharmacokinetics and pharmacogenetics on the efficacy of pranlukast in Japanese asthmatics. <i>Respirology (Carlton, Vic.)</i> 14(6) 822–827. DOI:<a href=\"https://doi.org/10.1111/j.1440-1843.2009.01552.x\">10.1111/j.1440-1843.2009.01552.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19703064/\">https://pubmed.ncbi.nlm.nih.gov/19703064</a></p></li><li><p>Lima, JJ (2007). Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. <i>Molecular diagnosis &amp; therapy</i> 11(2) 97–104. DOI:<a href=\"https://doi.org/10.1007/BF03256228\">10.1007/BF03256228</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17397245/\">https://pubmed.ncbi.nlm.nih.gov/17397245</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03DC02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pranlukast;
